IBDEI0KG ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9024,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,9024,1,4,0)
 ;;=4^N02.2
 ;;^UTILITY(U,$J,358.3,9024,2)
 ;;=^5015513
 ;;^UTILITY(U,$J,358.3,9025,0)
 ;;=N02.3^^69^617^73
 ;;^UTILITY(U,$J,358.3,9025,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9025,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,9025,1,4,0)
 ;;=4^N02.3
 ;;^UTILITY(U,$J,358.3,9025,2)
 ;;=^5015514
 ;;^UTILITY(U,$J,358.3,9026,0)
 ;;=N02.4^^69^617^72
 ;;^UTILITY(U,$J,358.3,9026,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9026,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,9026,1,4,0)
 ;;=4^N02.4
 ;;^UTILITY(U,$J,358.3,9026,2)
 ;;=^5015515
 ;;^UTILITY(U,$J,358.3,9027,0)
 ;;=N02.5^^69^617^77
 ;;^UTILITY(U,$J,358.3,9027,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9027,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,9027,1,4,0)
 ;;=4^N02.5
 ;;^UTILITY(U,$J,358.3,9027,2)
 ;;=^5015516
 ;;^UTILITY(U,$J,358.3,9028,0)
 ;;=N02.6^^69^617^74
 ;;^UTILITY(U,$J,358.3,9028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9028,1,3,0)
 ;;=3^Recurrent & perst hematur w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,9028,1,4,0)
 ;;=4^N02.6
 ;;^UTILITY(U,$J,358.3,9028,2)
 ;;=^5015517
 ;;^UTILITY(U,$J,358.3,9029,0)
 ;;=N02.7^^69^617^75
 ;;^UTILITY(U,$J,358.3,9029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9029,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,9029,1,4,0)
 ;;=4^N02.7
 ;;^UTILITY(U,$J,358.3,9029,2)
 ;;=^5015518
 ;;^UTILITY(U,$J,358.3,9030,0)
 ;;=N02.8^^69^617^80
 ;;^UTILITY(U,$J,358.3,9030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9030,1,3,0)
 ;;=3^Recurrent & perst hematur w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,9030,1,4,0)
 ;;=4^N02.8
 ;;^UTILITY(U,$J,358.3,9030,2)
 ;;=^5015519
 ;;^UTILITY(U,$J,358.3,9031,0)
 ;;=N02.9^^69^617^81
 ;;^UTILITY(U,$J,358.3,9031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9031,1,3,0)
 ;;=3^Recurrent & perst hematur w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,9031,1,4,0)
 ;;=4^N02.9
 ;;^UTILITY(U,$J,358.3,9031,2)
 ;;=^5015520
 ;;^UTILITY(U,$J,358.3,9032,0)
 ;;=N03.0^^69^617^18
 ;;^UTILITY(U,$J,358.3,9032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9032,1,3,0)
 ;;=3^Chr nephritic syndrome w/ minor glomerular abnormality
 ;;^UTILITY(U,$J,358.3,9032,1,4,0)
 ;;=4^N03.0
 ;;^UTILITY(U,$J,358.3,9032,2)
 ;;=^5015521
 ;;^UTILITY(U,$J,358.3,9033,0)
 ;;=N03.1^^69^617^17
 ;;^UTILITY(U,$J,358.3,9033,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9033,1,3,0)
 ;;=3^Chr nephritic syndrome w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,9033,1,4,0)
 ;;=4^N03.1
 ;;^UTILITY(U,$J,358.3,9033,2)
 ;;=^5015522
 ;;^UTILITY(U,$J,358.3,9034,0)
 ;;=N03.2^^69^617^14
 ;;^UTILITY(U,$J,358.3,9034,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9034,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,9034,1,4,0)
 ;;=4^N03.2
 ;;^UTILITY(U,$J,358.3,9034,2)
 ;;=^5015523
 ;;^UTILITY(U,$J,358.3,9035,0)
 ;;=N03.3^^69^617^15
 ;;^UTILITY(U,$J,358.3,9035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9035,1,3,0)
 ;;=3^Chr nephritic syndrome w/ diffuse mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,9035,1,4,0)
 ;;=4^N03.3
 ;;^UTILITY(U,$J,358.3,9035,2)
 ;;=^5015524
